Funding Statement: This supplement is developed from the content presented during a symposium held at the 52nd Annual Scientific Meeting of the American Headache Society®.
Pathophysiology of Chronic Migraine and Mode of Action of Preventive Medications
Version of Record online: 19 JUL 2011
© 2011 American Headache Society
Headache: The Journal of Head and Face Pain
Special Issue: Decoding Chronic Migraine: Translating Clinical Trial Data Into Optimal Outcomes With Novel Therapies
Volume 51, Issue Supplement s2, pages 84–92, July/August 2011
How to Cite
Mathew, N. T. (2011), Pathophysiology of Chronic Migraine and Mode of Action of Preventive Medications. Headache: The Journal of Head and Face Pain, 51: 84–92. doi: 10.1111/j.1526-4610.2011.01955.x
Jointly sponsored by the Annenberg Center for Health Sciences and CogniMed Inc.
This activity is supported by an independent educational grant provided by Allergan, Inc.
Conflict of Interest: Ninan T. Mathew, MD, FRCPC, has received research support from Allergan, Inc.; ENDO; GlaxoSmithKline; Merck & Co., Inc.; and Pfizer Inc. He serves on the speakers bureaus of ENDO; GlaxoSmithKline; and Merck & Co., Inc.
- Issue online: 19 JUL 2011
- Version of Record online: 19 JUL 2011
- Accepted for publication March 14, 2011.
- 3Pathophysiology of chronic migraine and mode of action of preventive medications. Presented at: Decoding Chronic Migraine: Translating Clinical Trial Data Into Optimal Outcomes With Novel Therapies; June 25, 2010; Los Angeles, CA..
- 10Is there a brainstem generator of chronic daily headache? J Headache Pain. 2000;2:67-71., , , , .
- 32Mechanisms of the antinociceptive effect of subcutaneous Botox®: Inhibition of peripheral and central nociceptive processing. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(Suppl. 2):R17. Abstract 33., , , , .